Apixaban to Prevent Heart Clots After a Heart Attack
Tests low-dose apixaban against standard care in adults after a front-wall heart attack.
Plain-language title generated from the registry record
Registry title: Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction
Key facts
- Where
- Karachi, PakistanSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06742567, who can take part
Where in Pakistan
- NICVD PakistanKarachi, PakistanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National Institute of Cardiovascular Diseases, Pakistan
- Trial code
- NCT06742567
- Record updated
- 19 December 2024
- Original description
The objective of this randomized controlled trial is to compare the safety and efficacy of low dose Apixaban (2.5 mg bid) in addition to guideline directed medical therapy vs guideline directed medical therapy alone in the prevention of left ventricular thrombus formation (after 30-days) following primary PCI in patients with acute anterior myocardial infarction with severe LV dysfunction.Read full original descriptionShow less
Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction: An Open Label, Randomized Clinical Trial (POTAMI)
The objective of this randomized controlled trial is to compare the safety and efficacy of low dose Apixaban (2.5 mg bid) in addition to guideline directed medical therapy vs guideline directed medical therapy alone in the prevention of left ventricular thrombus formation (after 30-days) following primary PCI in patients with acute anterior myocardial infarction with severe LV dysfunction.
Inclusion: Patients aged 18-65 years; Presenting with acute anterior STEMI; Severe LV dysfunction (EF<35%) with antero-apical akinesis, dyskinesis, or aneurysm; WIHTOUT evidence of LV thrombus.
Exclusion: Patients with previous anterior myocardial infarction or LAD revascularization procedures; History of recent CVA ( within past three months); Pregnant patients and those with hematological disorders; Recent ICH or major bleed requiring transfusion, low platelet counts <100,000; Patients with cardiogenic shock; Patients with LV thrombus; Patients with advanced CKD (Cr > 2 and those on hemodialysis); Patients with atrial fibrillation or other indications for chronic anticoagulation.